Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Dr. Reddy's Laboratories Ltd has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL_RI, for filing in highly regulated markets such as the United States, Europe and other regions.

Related Keywords

United States ,India ,Fresenius Kabi ,Jayanth Sridhar ,European Union ,Reddy Laboratories Ltd ,Reddy Laboratories ,Biologics License Application ,Marketing Authorisation Application ,Global Head ,Laboratories Limited ,Drreddyslaboratories ,Ine089a01023 ,Ardy ,Pharmaceuticals ,Clinicalstudies ,Rituximab ,Biosimilar ,